At WAT Medical, the focus is on developing innovative solutions that address common ailments while making a significant impact on the lives of individuals with rare conditions. The products, EmeTerm and HeadaTerm 2, are designed with this mission in mind, providing relief and support to those with Ehlers-Danlos Syndromes (EDS) and Hypermobility Spectrum Disorders (HSD).
EmeTerm: Advancing Relief for EDS and HSD Patients
EmeTerm is a pioneering anti-nausea wristband that functions by transmitting targeted electrical signals to the central nervous system. This mechanism effectively intercepts and delays the transmission of nausea signals from the brain to the stomach, substantially reducing nausea and preventing vomiting. Scientifically validated, EmeTerm has demonstrated efficacy in alleviating chemotherapy-induced nausea and post-operative nausea and vomiting.
Recognizing the unique challenges faced by EDS and HSD patients, WAT Medical has partnered with The Ehlers-Danlos Society to donate EmeTerm devices to those in need. The feedback from patients has been overwhelmingly positive. One EDS patient noted, "I haven't seen mention of this for nausea in other GP forums, but an EDS member mentioned that this is something they have tried and found helpful. They said 'Emeterm, which is vagal nerve stimulation, helps some people a lot with nausea, constipation, and gastroparesis.'"
Another patient commented, "We've been using it for about six weeks, and it is still working well for us on level 1." Parents of affected children have also expressed their gratitude: "My daughter started to use the Emeterm because her nausea was so bad none of the antiemetics she was prescribed worked for her. The relief from her gastroparesis in addition to the nausea relief was a very pleasant surprise." Another family remarked, "We find Emeterm works well for nausea and bowel problems."
HeadaTerm 2: Future Vision in EDS and HSD Support
HeadaTerm 2 is an FDA-approved neuromodulation device designed to provide drug-free relief and prevention of migraine headaches. By delivering precise electric impulses to nerves associated with migraine pain, HeadaTerm 2 offers a promising alternative to conventional migraine therapies. Clinical trials have shown a remarkable 69.66% decrease in pain among users, establishing HeadaTerm 2 as an effective remedy for acute migraine episodes.
Looking ahead, WAT Medical aims to extend the benefits of HeadaTerm 2 to the EDS and HSD communities. By actively participating in events organized by The Ehlers-Danlos Society and other charitable organizations, the company strives to raise awareness and provide access to effective, non-pharmacological treatment options for those suffering from chronic pain and migraines.
WAT Medical’s commitment to improving the quality of life for individuals with EDS and HSD is unwavering. Through innovative technology and community engagement, EmeTerm and HeadaTerm 2 are poised to continue making significant contributions to the lives of those affected by these rare conditions. With the support of the community, WAT Medical can bring hope and relief to those who need it most.
